These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12270783)

  • 1. Chemoprevention of superficial bladder cancer.
    Gee J; Sabichi AL; Grossman HB
    Crit Rev Oncol Hematol; 2002 Sep; 43(3):277-86. PubMed ID: 12270783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention of superficial bladder cancer.
    Kamat AM
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):799-808. PubMed ID: 14686702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer.
    Messing E; Kim KM; Sharkey F; Schultz M; Parnes H; Kim D; Saltzstein D; Wilding G
    J Urol; 2006 Aug; 176(2):500-4. PubMed ID: 16813878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention of bladder cancer.
    Grossman HB
    Urology; 2006 Mar; 67(3 Suppl 1):19-22; discussion 23-4. PubMed ID: 16530070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinoids in the chemoprevention of bladder cancer.
    Sabichi AL; Lerner SP; Grossman HB; Lippman SM
    Curr Opin Oncol; 1998 Sep; 10(5):479-84. PubMed ID: 9800121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective clinical trial of difluoromethylornithine (DFMO) in patients with resected superficial bladder cancer.
    Loprinzi CL; Messing EM
    J Cell Biochem Suppl; 1992; 16I():153-5. PubMed ID: 1305680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer.
    Solsona E; Iborra I; Dumont R; Rubio-Briones J; Casanova J; Almenar S
    J Urol; 2000 Sep; 164(3 Pt 1):685-9. PubMed ID: 10953125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of chemopreventive agents for bladder cancer.
    Kelloff GJ; Boone CW; Malone WF; Steele VE; Doody LA
    J Cell Biochem Suppl; 1992; 16I():1-12. PubMed ID: 1305671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprevention of bladder cancer.
    Kamat AM; Lamm DL
    Urol Clin North Am; 2002 Feb; 29(1):157-68. PubMed ID: 12109342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention of bladder cancer.
    Golijanin DJ; Kakiashvili D; Madeb RR; Messing EM; Lerner SP
    World J Urol; 2006 Nov; 24(5):445-72. PubMed ID: 17048030
    [No Abstract]   [Full Text] [Related]  

  • 11. Bladder cancer: chemoprevention, complementary approaches and budgetary considerations.
    Grossman HB; Stenzl A; Moyad MA; Droller MJ
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):213-33. PubMed ID: 18815935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bladder Cancer Chemopreventive Agents: Current Knowledge and Concepts.
    Khajeh NR; Khoyilar C; Wu Y; Spradling K; Zi X; Youssef RF
    Mini Rev Med Chem; 2018; 18(13):1143-1150. PubMed ID: 26975668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and management of superficial bladder cancer.
    Amling CL
    Curr Probl Cancer; 2001; 25(4):219-78. PubMed ID: 11514784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinoids in the prevention of bladder cancer.
    Nutting CM; Huddart RA
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):541-5. PubMed ID: 12113086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point.
    Decensi A; Torrisi R; Bruno S; Costantini M; Curotto A; Nicolò G; Malcangi B; Baglietto L; Bruttini GP; Gatteschi B; Rondanina G; Varaldo M; Perloff M; Malone WF; Bruzzi P
    Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1071-8. PubMed ID: 11045790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group.
    Kurth KH; Bouffioux C; Sylvester R; van der Meijden AP; Oosterlinck W; Brausi M
    Eur Urol; 2000; 37 Suppl 3():1-9. PubMed ID: 10828681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach.
    Schulze M; Stotz N; Rassweiler J
    J Endourol; 2007 Dec; 21(12):1533-41. PubMed ID: 18186695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy.
    Duque JL; Loughlin KR
    Urol Clin North Am; 2000 Feb; 27(1):125-35, x. PubMed ID: 10696251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant intravesicular pharmacotherapy for superficial bladder cancer.
    Lum BL; Torti FM
    J Natl Cancer Inst; 1991 May; 83(10):682-94. PubMed ID: 1827165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder cancer, 1996.
    Lamm DL; Torti FM
    CA Cancer J Clin; 1996; 46(2):93-112. PubMed ID: 8624800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.